Crossmark

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Crossref DOI link: https://doi.org/10.1186/s12885-023-10972-6

Published Online: 2023-05-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kehmann, Linde

Berres, Marie-Luise

Gonzalez-Carmona, Maria

Modest, Dominik P.

Mohr, Raphael

Wree, Alexander

Venerito, Marino

Strassburg, Christian

Keitel, Verena

Trautwein, Christian

Luedde, Tom

Roderburg, Christoph https://orcid.org/0000-0002-1409-7697
Funding

Funding for this research was provided by:

Servier

Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
License Information

Text and Data Mining valid from 2023-05-22

Version of Record valid from 2023-05-22
More Information

Article History

Received: 6 March 2022

Accepted: 16 May 2023

First Online: 22 May 2023

Declarations

:

: The study has been approved by the Ethik-Kommission an der Medizinischen Fakultät der Rheinisch-Westfälischen Technischen Hochschule Aachen (EudraCT-Nr. 2018–002936-26, Protocol-Nr. 17–157). Written informed consent need to be obtained from all study participants.

: N/A.

: Linde Kehmann is employee of Servier Deutschland GmbH.

Document is current

Any future updates will be listed below